About FDA

Payor Communication Task Force

Background

CDRH established the Payor Communication Task Force to facilitate communication between device manufacturers and payors to potentially shorten the time between FDA approval or clearance and coverage decisions. By communicating earlier, manufacturers may design their clinical trials to produce the data required for regulatory approval or clearance and positive coverage determinations, which may expedite patient access.

Payors include public payors such as Centers for Medicare & Medicaid Services (CMS), private health plans, health technology assessment groups, and others who provide input into coverage and reimbursement decisions.

FDA's Center for Devices & Radiological Health (CDRH) evaluates the safety and effectiveness of medical devices for use in the U.S. Usually after FDA approval or clearance, other organizations—for example, public and private organizations that pay for health care (payors) and the professionals who provide health care (providers)—decide whether to cover, pay for, or use a device. Often, the data submitted by medical device manufacturers to demonstrate safety and effectiveness to the FDA may not include data needed by payors to make coverage determinations. As a result, after FDA approval or clearance, there may be a delay in coverage, payment and use decisions that may ultimately delay patient access to medical devices.

Opportunities to Obtain Payor Input

CDRH has a voluntary opportunity for medical device sponsors to obtain payor input on clinical trial design or other plans for gathering clinical evidence needed to support positive coverage decisions. All regulatory discussions will continue to follow the processes established within the CDRH Pre-Submission Program. Organizations willing to join CDRH Pre-Submission meetings are listed below. CDRH has an open request for additional coverage organizations that evaluate clinical evidence and make coverage recommendations or decisions for payors and health plans to join this opportunity.

NOTE: This is a voluntary opportunity for both the medical device sponsors and coverage organizations. The decision of a medical device sponsor to participate or not to participate in this opportunity will not alter the regulatory and evidentiary standards FDA uses for decision making. Inclusion on this list does not imply or constitute any endorsement or relationship between these organizations and the FDA. The FDA has not independently verified that these organizations evaluate clinical evidence used to support payor coverage decisions for medical devices or make coverage recommendations to or decisions for payors and health plans regarding medical devices.

List of Current Participants:

Company Name Company Mailing Address
BlueCross BlueShield Association
(Health Technology Assessment)
225 North Michigan Avenue
Chicago, IL 60601
CareFirst BlueCross BlueShield
(Payor Provider Organization)
1501 S. Clinton Street, 17th Floor
Baltimore, MD 21224
Center for Medicare & Medicaid Services (CMS)
(Payor Provider Organization)
7500 Security Boulevard,
Baltimore, MD 21244
Duke Evidence Synthesis Group,
Duke Clinical Research Institute,
Duke University
(Health Technology Assessment)
2400 Pratt Street
Duke Clinical Research Institute
Durham, NC 27705
ECRI Institute Headquarters
(Health Technology Assessment)
5200 Butler Pike
Plymouth Meeting, PA 19462-1298
Humana
(Payor Provider Organization)
500 West Main Street
Louisville, KY 40202
Kaiser Permanente
(Payor Provider Organization)
393 East Walnut Street
Pasadena, CA 91188
National Institute for Health and Care Excellence (NICE)
(Health Technology Assessment)
Level 1A City Tower,
Piccadilly Plaza,
Manchester, M1 4BT,
United Kingdom
United Health Group
(Payor Provider Organization)
9900 Bren Road East
Minnetonka, MN 55343

How to Apply

Medical device sponsors may contact CDRHPayorCommunications@fda.hhs.gov to request that a listed respondent join their Pre-Submission meeting. This request must be received prior to submitting your Pre-Submission to CDRH for review. Once we receive your request, we will work with those selected to gauge their interest and availability. If you have any questions about this opportunity, please email CDRHPayorCommunications@fda.hhs.gov.

Parallel Review with Centers for Medicare and Medicaid Services (CMS)

In 2011, FDA and CMS introduced the Parallel Review Pilot Program (Parallel Review), which established a mechanism for FDA and CMS to simultaneously review the submitted clinical data to help decrease the time between FDA's approval of a premarket application and the subsequent CMS national coverage determination (NCD).  In October 2016, the FDA and CMS announced the Parallel Review program will be fully implemented and extended indefinitely.

Parallel Review has two stages:

  1. FDA and CMS meet with the manufacturer to provide feedback on the proposed pivotal clinical trial within the CDRH Pre-Submission Program.
  2. FDA and CMS concurrently review (“in parallel”) the clinical trial results submitted in the PMA or De Novo request.

FDA and CMS will independently review the data to determine whether it meets their respective Agency's standards and communicate with the manufacturer during their respective reviews.

How to Apply

Manufacturers interested in parallel review should submit an email request for parallel review to Parallel-Review@fda.hhs.gov that indicates their interest in the program and includes the following:

  • Name of the sponsor/requester and relevant contact information;
  • Device name, and proposed indications for use/intended use;
  • Device description including stage of development of the technology;
  • Submission number (if applicable); and Brief statement explaining why the device is an appropriate candidate for Parallel Review (be sure to address each of the four criteria outlined below).

Preference for enrollment in Parallel Review is given to devices that meet all the following criteria:

  1. The manufacturer intends to meet jointly with FDA and CMS using FDA's Pre-Submission program or other mechanisms that allow for meetings of the three parties to gather and incorporate feedback about the design and analysis of their pivotal clinical trial to support a marketing application and a National Coverage Determination.
  2. The medical device will require an original or supplemental application for premarket approval (PMA) or the granting of a de novo request;
  3. The medical device is not excluded by statute from Part A and/or Part B Medicare coverage (and the request for parallel review includes a list of Part A and/or Part B Medicare benefit categories, as applicable, into which the manufacturer believes the medical device falls); and
  4. The medical device addresses the public health needs of the Medicare population (and the request for parallel review includes an explanation of how).

FDA intends to respond by email to all requests within 30 calendar days, and may contact the sponsor/requestor to request additional information.

Participation in Parallel Review is voluntary and does not change the existing separate and distinct review standards for FDA device approval or clearance and CMS national coverage determination. For questions or additional information on the Parallel Review, contact Parallel-Review@fda.hhs.gov.

Stakeholder Engagement

CDRH's Payor Communication Task Force co-hosted a Payor Summit for Medical Devices on December 14, 2016. In this meeting, we discussed ways to further improve patient access to safe and effective medical devices. Regulators, payors, patient advocacy groups, professional societies, coding experts, heath technology assessment groups, small and large businesses, and venture capitalist/investors considered barriers and challenges to patient access and brainstormed potential solutions. From this meeting, we collectively decided that CDRH will prioritize these action items:

  • Create a Medical Device Innovation Hub - We will establish a program/group intended to improve patient access to medical devices through addressing the many different aspects of the evaluation process including FDA clearance/approval, evidence generation, healthcare technology assessment, coding, coverage, and payment.
  • Match Technologies with Integrated Healthcare Providers - Explore opportunities to identify needs of integrated healthcare payor providers and match those needs with specific technologies, allowing for coverage with evidence development (or similar process) to determine if the technology addresses the needs of the integrated healthcare provider.

For questions, additional information, or to request our presence at an event, please email us at CDRHPayorCommunications@fda.hhs.gov. Please note, all formal speaking requests will need to follow the procedures outlined here.


Related Links

Page Last Updated: 10/23/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English